NEU.WAR Neuca S.A.

Healthcare Consumer Staples Distribution & Retail Warsaw Stock Exchange
Add to portfolio Ask AI about NEU.WAR
703.00 PLN
Close of Oct 29, 2026
638.76 828.93
Market cap
PLN 3.18B
P/E
16.5x
P/B
2.85x
ROE
19.5%
Dividend yield
2.27%
Fundamental score
2.3/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is NEU.WAR undervalued?

Graham number
Price703.00
Graham value486.23
Premium44.6%

NEU.WAR trades 44.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neuca S.A. fundamental analysis

11 of 22 checks passed

ROE 1/2

Moderate return on equity (19.5%), between 10% and 20%.

ROA 0/1

Return on assets (3.5%) is below the industry median (5.9%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (-10.0%) is not above the 5-year average (1.3% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (-10.0%) is below the industry median (-3.2%).

Revenue Growth 1/2

Revenue grew 6.7% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (71.3%), up to 100%.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 0/1

EBIT is 4.8x against interest expense, below 5x.

PE vs Market 0/1

PE (16.5x) is above the market median (11.6x).

PE vs Industry 0/1

PE (16.5x) is above the industry median (16.5x).

PBV 0/1

Price to book (2.8x) is above the industry median (2.6x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 47.0, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 13.10, above 1.

Dividend Yield 1/2

Dividend yield (2.3%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 2/2

Dividends paid without a cut of more than 10% for 11 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 46.3%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Neuca S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neuca S.A.

NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company offers Rx, OTC drugs, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, …

Full company profile